Provided by Tiger Trade Technology Pte. Ltd.

AlphaTON Capital Corp.

0.5200
+0.01803.59%
Pre-market: 0.4980-0.0220-4.23%06:48 EST
Volume:514.95K
Turnover:264.12K
Market Cap:6.92M
PE:-0.06
High:0.5320
Open:0.5090
Low:0.4818
Close:0.5020
52wk High:15.82
52wk Low:0.4618
Shares:13.31M
Float Shares:11.92M
Volume Ratio:0.75
T/O Rate:4.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.5740
EPS(LYR):-5.7202
ROE:-311.00%
ROA:-34.26%
PB:0.72
PE(LYR):-0.09

Loading ...

Company Profile

Company Name:
AlphaTON Capital Corp.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
4
Office Location:
Clarence Thomas Building,P.O. Box 4649,Road Town,Tortola,British Virgin Islands
Zip Code:
VG1110
Fax:
- -
Introduction:
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Directors

Name
Position
Alexander Pickett
Chief Executive Officer and Director
Justin Stebbing
Director and Chairman of the Board
F. Daniel Siciliano
Director
Gregory H. Bailey
Director
James Mellon
Director
Jean Christophe Renondin
Director

Shareholders

Name
Position
Alexander Pickett
Chief Executive Officer and Director
Wes Levitt
Chief Financial Officer
Robert Kramer
Chief Scientific Officer